Filing Flows › IGC Pharma (IGC) › Q2 2026 › vs Q2 2025
IGC Pharma (IGC) Q2 2026 vs Q2 2025 (year over year)
IGC Pharma's revenue fell $63K (-19%) from $328K in Q2 2025 to $265K in Q2 2026. The biggest changes: White Labeling Services −$66K (-20%); Wellness and Lifestyle +$3K (+50%).
IGC Pharma, Q2 2026: revenue $265K (-19% year over year), net loss $2.9M, operating cash flow −$1.4M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| White Labeling Services | $256K | $322K | −$66K | -20% |
| Wellness and Lifestyle | $9K | $6K | $3K | +50% |
| Revenue | $265K | $328K | −$63K | -19% |
| Net loss | $2.9M | $1.6M | $1.3M | +84% |
| Costs & expenses | $3.2M | $2.2M | $968K | +43% |
| Operating costs | $3.0M | $2.2M | $816K | +37% |
| Interest & other, net | $152K | −$306K | $458K | — |
| Cost of revenue | $217K | $174K | $43K | +25% |
| Research & development | $1.4M | $851K | $539K | +63% |
| SG&A | $1.4M | $1.2M | $234K | +19% |
| Operating cash sources | $2.9M | $1.6M | $1.3M | +84% |
| Depreciation & amortization | $56K | $141K | −$85K | -60% |
| Share-based compensation | $200K | $4.7M | −$4.5M | -96% |
| Working capital & other | $1.3M | −$4.6M | $6.0M | — |
| Cash used in operations | $1.4M | $1.4M | −$57K | -4% |
| Net loss absorbed | $2.9M | $1.6M | $1.3M | +84% |
Questions
How much did IGC Pharma's revenue grow year over year in Q2 2026?
IGC Pharma's revenue fell $63K (-19%) from $328K in Q2 2025 to $265K in Q2 2026.
What drove IGC Pharma's revenue change in Q2 2026?
White Labeling Services −$66K (-20%); Wellness and Lifestyle +$3K (+50%).